AU2023209973A1 - Oligonucleotide modulators activating utrophin expression - Google Patents

Oligonucleotide modulators activating utrophin expression Download PDF

Info

Publication number
AU2023209973A1
AU2023209973A1 AU2023209973A AU2023209973A AU2023209973A1 AU 2023209973 A1 AU2023209973 A1 AU 2023209973A1 AU 2023209973 A AU2023209973 A AU 2023209973A AU 2023209973 A AU2023209973 A AU 2023209973A AU 2023209973 A1 AU2023209973 A1 AU 2023209973A1
Authority
AU
Australia
Prior art keywords
sarna
cell
expression
gene
utrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023209973A
Other languages
English (en)
Inventor
Moorim KANG
Longcheng Li
Robert PLACE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ractigen Therapeutics
Original Assignee
Ractigen Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ractigen Therapeutics filed Critical Ractigen Therapeutics
Publication of AU2023209973A1 publication Critical patent/AU2023209973A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2023209973A 2022-01-20 2023-01-13 Oligonucleotide modulators activating utrophin expression Pending AU2023209973A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022072958 2022-01-20
CNPCT/CN2022/072958 2022-01-20
PCT/CN2023/072076 WO2023138502A1 (en) 2022-01-20 2023-01-13 Oligonucleotide modulators activating utrophin expression

Publications (1)

Publication Number Publication Date
AU2023209973A1 true AU2023209973A1 (en) 2024-09-05

Family

ID=87347803

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023209973A Pending AU2023209973A1 (en) 2022-01-20 2023-01-13 Oligonucleotide modulators activating utrophin expression

Country Status (10)

Country Link
US (1) US20250101421A1 (https=)
EP (1) EP4466359A1 (https=)
JP (1) JP2025504474A (https=)
KR (1) KR20250005567A (https=)
CN (1) CN118829728A (https=)
AU (1) AU2023209973A1 (https=)
CA (1) CA3249545A1 (https=)
MX (1) MX2024008939A (https=)
TW (1) TW202338088A (https=)
WO (1) WO2023138502A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025201529A1 (en) * 2024-03-29 2025-10-02 Ractigen Therapeutics Compounds for synthesizing modified small activating rna molecules, modified small activating rna molecules and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5931720B2 (ja) * 2009-05-08 2016-06-08 クルナ・インコーポレーテッド Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
EA201492122A1 (ru) * 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии utrn
US20170044540A1 (en) * 2014-04-22 2017-02-16 Mina Therapeutics Limited Sarna compositions and methods of use
WO2021230385A1 (en) * 2020-05-15 2021-11-18 Astellas Pharma Inc. Method for treating muscular dystrophy by targeting utrophin gene

Also Published As

Publication number Publication date
TW202338088A (zh) 2023-10-01
JP2025504474A (ja) 2025-02-12
MX2024008939A (es) 2024-07-29
KR20250005567A (ko) 2025-01-09
EP4466359A1 (en) 2024-11-27
WO2023138502A1 (en) 2023-07-27
US20250101421A1 (en) 2025-03-27
CN118829728A (zh) 2024-10-22
CA3249545A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
US20250333734A1 (en) Antisense oligonucleotides for the treatment of Stargardt disease
WO2023280190A1 (en) Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof
WO2024001172A1 (en) Oligonucleotide modulators activating complement factor h expression
US20180237775A1 (en) Antisense oligonucleotides and uses thereof
TW202039848A (zh) 肌肉生長抑制素訊號傳導抑制劑
AU2016337034A1 (en) Antisense oligonucleotides for use in treating Alzheimer's disease
WO2023138502A1 (en) Oligonucleotide modulators activating utrophin expression
WO2024001170A1 (en) Small activating nucleic acid molecule and use thereof in treatment of hereditary angioedema
EP4669754A1 (en) OLIGONUCLEOTI TARGETING SOD1
US20250084420A1 (en) Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
HK40118443A (zh) 活化抗肌萎缩蛋白相关蛋白表达的寡核苷酸调节剂
WO2024183714A1 (en) Oligonucleotide modulators activating factor vii expression and use thereof in treatment of hemophilia
HK40122862A (zh) 激活补体因子h表达的寡核苷酸调节剂
WO2025237990A1 (en) Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
CA2999192C (en) Antisense oligonucleotides hybridizing with a key element of the polyadenylation region of a dux4 pre-mrna and uses thereof
KR20220155585A (ko) Sirt1 발현을 사용하는 진단 방법
KR20220154772A (ko) Pgc-1a 발현을 사용하는 진단 방법
IL324749A (en) Methods for targeting lipid nanoparticles in vivo
HK40119190A (zh) 小激活核酸分子及其在治疗遗传性血管性水肿中的用途